Deals, Insiders

Going gangbusters: The top 20 biotech platform deals by upfront cash

Fortunately, right at the time Regeneron and Alnylam were getting ready to break the news about their billion-dollar partnership, Chris Dokomajilar at DealForma was working up a top-20 list of platform deals from the last decade.

With $800 million for the upfront and equity, the new deal lands right at the number 2 spot for the industry, highlighting just how unusual this pact is for such an early-stage alliance. It’s also Regeneron’s first big turn as the buyer.

Drug developers have been moving upstream more and more, and along wth a burst of M&A we're also seeing the early, early deals going gangbusters, as Dokomajilar notes in his assessment of the current trends:

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->